Who are Brimonidine purite 0.15%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nebulized lidocaine and dexmedetomidine, Sufentanil and dexmedetomidine, Intra-nasal Dexmedetomidine, transdermal clonidine, IV acetaminophen & IV dexmedetomidine, Oxymetazoline gel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brimonidine-purite-0-15.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Brimonidine purite 0.15% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brimonidine purite 0.15% (Brimonidine purite 0.15%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist. Area: Ophthalmology.

marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Brimonidine purite 0.15% (Brimonidine purite 0.15%) — Northwestern Ophthalmic Institute S.C.. Brimonidine is an alpha-2 adrenergic agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Brimonidine purite 0.15% TARGET	Brimonidine purite 0.15%	Northwestern Ophthalmic Institute S.C.	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Nebulized lidocaine and dexmedetomidine	Nebulized lidocaine and dexmedetomidine	Ain Shams University	marketed	Local anesthetic and sedative-analgesic combination	Voltage-gated sodium channels (lidocaine); alpha-2 adrenergic receptors (dexmedetomidine)
Sufentanil and dexmedetomidine	Sufentanil and dexmedetomidine	Obstetrics & Gynecology Hospital of Fudan University	marketed	Opioid agonist and alpha-2 adrenergic agonist combination	Mu opioid receptor and alpha-2 adrenergic receptor
Intra-nasal Dexmedetomidine	Intra-nasal Dexmedetomidine	University of Massachusetts, Worcester	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
transdermal clonidine	transdermal clonidine	Peking University People's Hospital	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
IV acetaminophen & IV dexmedetomidine	IV acetaminophen & IV dexmedetomidine	Beth Israel Deaconess Medical Center	marketed	Analgesic/sedative combination	COX enzymes (acetaminophen); alpha-2 adrenergic receptors (dexmedetomidine)
Oxymetazoline gel	Oxymetazoline gel	RDD Pharma Ltd	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist class)

USWM, LLC (dba US WorldMeds) · 2 drugs in this class
China International Neuroscience Institution · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
Eye Therapies, LLC · 1 drug in this class
Galderma R&D · 1 drug in this class
Guangzhou Women and Children's Medical Center · 1 drug in this class
Derm Research, PLLC · 1 drug in this class
Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 drug in this class
KK Women's and Children's Hospital · 1 drug in this class
American University of Beirut Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brimonidine purite 0.15% — Competitive Intelligence Brief. https://druglandscape.com/ci/brimonidine-purite-0-15. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab